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Application of Bone Substitutes 
and Its Future Prospective in 
Regenerative Medicine
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Abstract
Bone is a hard and dense connective tissue that supports and maintains the 
body structure and functions. Several factors like aging, drugs, hormonal changes, 
and physical activities lead to several kinds of bone injuries/fracture. To address 
these problems, autologous bone graft is considered an ideal material. However, 
limited availability and complications related to its harvesting process like donor 
site morbidity and pain limit the use of autologous bone graft in bone regeneration. 
With increasing advances in technology, several bone substitute materials such as 
synthetics, bioceramics, and polymers are emerging as a substitute of auto- or allog-
enous bone for the treatment of bone defect. These bone substitute materials should 
be biocompatible, bioresorbable, osteoconductive, osteoinductive, and support the 
ingrowth of new bone. In this chapter, we summarize the currently available bone 
graft and bone substitute materials including biological and bio-inorganic factors. 
An overview of the associated advantages, challenges, and future perspectives to 
clinical implication is also discussed.
Keywords: autograft, allograft, growth factors, bone graft substitute,  
tissue engineering
1. Introduction
Bone is a part of vertebrate skeleton. It plays a multitude of important roles in 
the body like imparting structural support, protection of organs, acting as a site 
for production of blood cells, and also as repertoire of minerals. Bones comprise 
differentiated cell types, blood vessels, protein, minerals, and vitamins that facili-
tate their growth and repair system [1]. Bones have an inner and outer layer. The 
hard-outer layer of bone which is called “cortical bone” is usually tough and strong, 
whereas the inner spongy part is called “trabecular bone” and is lighter and less 
dense. Each of these parts comprises different cell types, nonmineral proteinaceous 
matrix (osteoid), and matrix-deposited inorganic minerals. Another important 
concept in bone biology and understanding its transformational changes is that 
of modeling and remodeling. The scenario where the sites of bone formation and 
resorption are different surfaces of the bone is called bone modeling. This is respon-
sible for increased length and girth of long bone, leading to skeletal development 
and changes. Bone remodeling on the other hand is important for maintenance of 
bone mass in adults by replacement of old bone tissue with new ones [2]. Several 
factors which affect bone, muscles, and joints are responsible for causing diseases 
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like osteoarthritis (degenerative joint disease), rheumatoid arthritis (autoimmune 
disease), fibromyalgia (chronic condition of pain in bones, muscles, and tender 
areas with fatigue) and bone fractures. Aging plays an important role in mani-
festation of bone-related diseases along with other sub-factors like lifestyle, level 
of activity, family history, level of physical activity, drug usage, etc. However, in 
certain clinical situations, the natural bone repair may be too slow or inadequate; 
therefore, an alternative bone grafting strategy is required to address this problem.
2. Bone graft
In 1861, a surgeon from Lyon, France named Leopold Ollier was the first to 
describe the term bone graft (French: “greffe osseuse”) in his document “Traité de 
la régénération des os” [3]. It was considered a surgical procedure to promote bone 
healing for several reasons, like injury and disease utilizing a bone transplant.
Bone graft is the alternative choice to address the problem associated with 
bone disease. Bone grafts are basically bone-like materials that come from living 
donor, post mortem donors, or artificially constructed, which are used for healing, 
strengthening, or improvement of bone function in disease or injury.
2.1 Properties of ideal bone graft
The ideal bone substitute material should exhibit several important properties [4, 5]. 
This includes:
i. Biocompatibility—The graft should not evoke an immune response against 
the implanted tissue.
ii. Durability—The graft should be able to maintain its shape and volume over time 
without loss of its structural properties.
iii. Vascularity and angiogenesis—Porosity is important to maintain the proper 
transport of nutrients and oxygen for survival of the cells and tissues. A 
porous structure of at least 100 μm diameter is recommended. It has also 
been shown that supports with multiple apertures are preferred over one 
large pore. Also, a polymeric, ceramic, or composite material is preferred 
over a metallic one as the latter might not fuse completely and dissociate 
after implantation. Although most scaffold (structural support) materials 
do not induce angiogenesis, it is an indispensable requirement to meet high 
blood demands in bone tissue. The initial inflammatory response activates 
neovascularization, yet it takes several steps to form a vascular network. 
The established role of proinflammatory response is their catabolic effect 
on bone and premature failure of bone implants. However, recently in 
opposition to the conventional unregulated, destructive effect of inflam-
matory cytokines, its regulated role aiding towards fracture healing has 
been suggested [6–8]. The acute inflammation initiates the recruitment of 
MSCs, fibroblasts, and osteoprogenitor cells to promote bone regeneration 
[9]. The early phase of bone injury includes the inflammation phase where 
IL-1, prostaglandins, TNF-α, and other proinflammatory molecules recruit 
inflammatory cells and induce angiogenesis. IL-6 triggers angiogenesis by 
stimulating release of VEGF [8]. A recent study by Anghelescu et al. shows 
tissue formation exceeding the catabolic action of inflammation and it might 
be limited to specific allografts only.
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iv. Bio-absorbability—Another important feature of a substitute material is that it 
should get absorbed and provide the space for new bone formation. However, 
the duration of availability largely depends upon the site of surgery. The spi-
nal fusion requires the material to be degraded after 9 months or longer while 
in skull or maxillofacial bone the required time period is around 3–6 months.
v. Cost efficiency and availability—The material should be reasonable to be 
purchased and used.
Besides the above-mentioned characteristics, the ideal bone substitutes must 
strengthen bone healing by following the mechanism which involves osteogenesis, 
osteoinduction, and osteoconduction [10], which are mentioned here:
vi. Osteogenesis (acts as the origin or source)—The process where cellular ele-
ments from the host or graft donor provide the material to synthesize new 
bone at the graft site is called osteogenesis. Various autografts and stem cell 
transplants fall under this category.
vii. Osteoinduction (acts as initiator)—The process resulting in differentiation of 
recruited mesenchymal stem cells into chondroblast and osteoblast, which 
forms the new bone, is called osteoinduction. It is regulated essentially by 
various factors like bone morphogenetic proteins (BMP)-2, -4, -7, platelet-
derived growth factor (PDGF), parathyroid hormone (PTH), etc.
viii. Osteoconduction (provides direction)—A degradable support or scaffold mate-
rial which provides the surface for the production of new bone. It also exhibits 
osteoconductive properties. These may include metals and synthetic polymers, 
and most frequently used osteoconductive materials include calcium phosphate 
ceramics such as hydroxyapatite, calcium sulfate, and bioactive glass-ceramics.
Most widely used bone grafts (Figure 1) are mentioned below in detail.
Figure 1. 
Classification of bone grafting substitutes.
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3. Autograft
The autologous bone grafting as the name suggests ‘auto’ (self) involves tak-
ing up tissue from one anatomical location and transplanting it to another in the 
same patient. The method dates back to 1821 when Walther repaired the holes in a 
patient’s skull using the original bone plug [11, 12]. The method is still considered to 
be a ‘gold standard ‘as there is no immunogenic response against patient’s own tissue 
[13]. Thus, no graft rejection or histocompatibility issues are conferred. Moreover, 
it manifests the properties of an ideal bone graft, that is, osteogenesis, osteoinduc-
tion, and osteoconduction. However, it is not a straightforward path to follow 
and comes with a set of limitations associated with it. This includes an additional 
operative pain at donor site, increased blood loss, and also possible injury to nearby 
blood vessels. Besides, the inappropriate availability of tissue amount especially 
from infants and older patients results in added trouble [14, 15].
3.1 Autograft-based substitute
It is considered as a gold standard to treat bone defects due to their established 
osteoconductive and osteoinductive properties with reduced histocompatibility 
issue. Although it also has inherent drawbacks associated with issues of high post-
operative pain, donor site morbidity, muscle weakness, infection, high cost, and 
longer recovery periods limit its application.
Some of the common advantages and disadvantages associated with autograft 
are listed in Table 1.
3.2 Types of autografting commonly used are
3.2.1 Cancellous autograft
This is the most common procedure among autografts and has shown suc-
cess for various purposes majorly nonunions. It starts with hematoma formation 
resulting in recruitment of mesenchymal stem cells (MSCs), while simultane-
ously, necrotic graft is eliminated by macrophages [16, 17]. Neovascularization 
also takes place along with this, and finally, osteoid produced by osteoblasts lining 
the dead trabeculae forms new bone through mineralization, which takes a period 
ranging from 6 to 12 months post-operation [18]. The most common donor site 
is the iliac crest due to large surface of trabecular architecture and availability of 
growth factors [19, 20]. Recent report showed superior osseous bridging after 
bilateral tibial tuberosity advancement (TTA) over no graft in dogs [21]. Earlier, 
bone union was observed in graft harvested from scaphoid nonunion distal radius 
or iliac crest and headless compression screw to treat scaphoid nonunion [22]. 
Although being the gold standard, the limitation of the amount and donor site 
morbidity hinders its use.
Advantages Limitations
Osteogenic Donor site pain
Osteoconductive Increased blood loss
Osteoinductive Inappropriate amount of tissue availability
No graft rejection Increased risk of nerve injury
Table 1. 
Common advantages and disadvantages associated with an autograft.
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3.2.2 Cortical autograft
It shows creeping substitution, that is, deposition of new bone along with slow 
resorption of the graft. The process provides distinguished structural support. This 
graft also faces limited supply of osteoblasts and revascularization is impeded too.
3.2.3 Vascularised autograft
This type of graft promotes fracture healing and minimizes loss of bone strength 
after post-implantation. However, this graft also faces technical challenges for the 
preservation of graft’s osteocytes and osteoprogenitor cells.
4. Allograft
The second category of natural bone grafts is allograft, where tissue from another 
individual (donor) has to be taken for grafting. The term allograft (‘allo’ (other)) 
means harvesting tissue from different individuals to transplant in the subject. Bone 
harvested from cadavers in different bone banks is the major source of different 
allografts. Apart from the above-mentioned category, freeze dried (lyophilized) and 
frozen bones are also used in spine graft surgeries. Allografts are considered more 
advantageous as they are considered less stressful to the patient. However, they are 
also plagued with problems of availability and immune rejection. The first report of 
allograft usage can be dated back to 1800s, when Macewen reported the grafting of 
tibial fragments to a child [23]. Experimentation reported by Bauer in the beginning 
of twentieth century marks the starting of the bone bank concept, where he stored 
bone tissues for weeks in refrigerated condition and then used them for implantation 
in dogs. It was also established that chilling and boiling of bone tissues before using 
them as allografts led to destruction of their endogenous proteins and other factors 
resulting in poor and slow recovery [24]. The necessities posed by the devastation of 
World War II resulted in advancement and growth in the bone banking approach, 
with refinement of methods like autoclaving, freeze-drying, irradiating, demineral-
izing, and chemical treatment of the bone [25]. The advancement made during the 
war period continued with focus on civilian need and further refinement of the 
banking approach [23]. Pros and cons of allografts can be summarized in Table 2.
4.1 Types of allografting commonly used are
4.1.1 Cancellous bone graft
This is primarily an osteoconductive graft, devoid of growth factors (not osteo-
inductive), and like cancellous autograft, it also provides less mechanical support 
[26]. It is prepared in small cubicle form, thus sometimes called ‘croutons’ and is 
Advantages Disadvantages
Less chance of donor morbidity Chances of disease transmission
No size limitation Possibility of host immune response
Less surgical intervention High cost
Cosmetically better results Delay in incorporation
Reduce period for rehabilitation Local bone resorption
Table 2. 
Common advantages and disadvantages associated with an allograft.
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now marketed in varied sizes as chips or crushed form. It involves an initial cascade 
of inflammatory events leading to formation of a fibrous tissue around the graft, 
preventing complete integration of the graft. The survival and efficiency depend 
a lot on processing and storage conditions of the grafts. Freeze drying is the most 
common method of preservation of cancellous graft, which may result in destruc-
tion of osteoprogenitor cells and osteoinductive factors [27, 28].
4.1.2 Cortical bone graft
This shows a creeping substitution like its autograft counterpart, thus leading 
to bone healing in spite of an initial inflammatory response. It also provides struc-
tural support and thus can be utilized for load-bearing areas [10].
Both allograft and autograft have their own advantages and disadvantages. 
However, research is being carried out to search the materials which can be used as 
a substitute to replace the function of auto- and allograft. These substitutes pos-
sess the properties of one’s own bone, which stimulate bone healing and provide a 
strong and biologically compatible environment for the growth of new bone.
5. Bone graft substitute
The bone graft substitute is basically a synthetic inorganic or biologically 
organic combination, which guides to stimulate bone healing and fill bone defects. 
A good bone grafting substitute should have low immunogenicity and higher 
biocompatibility, and at the same time, it should be able to mold itself according to 
grafting needs. Bone grafts find application and are primarily used for linkage and 
splintage and help in promoting ontogenesis. In the case of linkage, bone grafts are 
utilized for filling cavities or defects in bone, replacement of crushed bone, and 
arthrodesis. While splintage-related grafting protocols are utilized for nonunion 
bone deformities and arthrodesis [29]. An understanding of bone formation, 
process of osteogenesis, osteoinduction, and osteoconduction is a prerequisite 
for appreciating the biology of graft substitution. The type of graft used and its 
physicochemical properties play an important role in its success. On a global scale, 
around 2.2 million graft substitutions are performed annually with 9 out of 10 
falling under the category of allograft or autografts. This bone grafting procedure 
typically follows the multistep cascade:
• Accumulation of inflammatory cells takes place due to induction by exogenous 
graft material, which is followed by chemotaxis reaction by mesenchymal stem 
cells. After that, the host cells differentiate into chondroblasts and osteoblasts 
with the stimulation of several osteoinductive factors [30].
• The osteoinductive matrix serves as a scaffold for supporting progenitor cells and 
osteoblasts. It also provides a porous structure, which helps in migration of new 
cells.
• The osteoblast cells start the formation of new bone under suitable conditions.
• Lastly, the osteoinductive proteins start stimulating the differentiation of osteo-
blasts. This leads to initialization of bone graft revascularization and necrotic 
graft resorption. As a result, bone production followed by bone remodeling 
started from the osteoblasts on the graft’s three-dimensional structure [31]. An 
outline of bone graft substitute process is shown in Figure 2.
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Broadly, the substitute materials can be categorized as natural and synthetic 
grafts. Under the natural grafting substitutes fall autografts and allografts.
5.1 Natural substitute material
5.1.1 Factor-based substitutes
Factor-based bone grafts include natural and recombinant growth factors and 
hormones, which are generally used alone and/or together with other materials. 
The bone morphogenetic proteins (BMPs), platelet-derived growth factor (PDGF), 
parathyroid hormone (PTH), transforming growth factor-beta proteins (TGF-β), 
and many more come under this category. This group too does not come without 
associated disadvantages, such as protein instability, risk of uncontrolled prolifera-
tion or cancer, and high cost.
5.1.1.1 Bone morphogenic proteins
Nearly 30 human proteins fall under the BMP name and this group comprises the 
largest division of transforming growth factor (TGF)-β family of ligands. Since the 
last 40 years, the significance of BMP signaling in skeletal development has received 
immense approval [32]. It was first identified as a substance in extracellular matrix 
of bone, which stimulates new bone formation by Marshall R. Urist, and later named 
BMPs. In the United States, in 2002, the Food and Drug Administration (FDA) 
approved the first bone graft substitute, which was the recombinant human (rh)
BMP-2 for single-level anterior lumbar interbody fusion (ALIF) within a titanium 
cage of implant grade. Subsequently, the increased use of BMP-2 for various spine 
Figure 2. 
Schematic representation shows the process of bone graft substitues.
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fusion injuries as an alternative to autograft acted to be a savior as bone substitute. 
Despite that, starting from 2006, independent research groups started reporting 
complications associated with the use of rhBMP-2. The side effects ranged from 
seroma formation [33, 34], ectopic bone growth [35–37], osteolysis [38, 39], and 
increased risk of cancer [40, 41]. This led to a systematic review and meta-analysis, 
which was reported in Annals of Internal Medicine in June 2013. It was conducted 
as joint work of Medtronic and Yale University Open Data Access Project (YODA), 
and reported biased results in earlier industry-funded publications [42, 43]. Now, 
the use of rhBMP-2 (INFUSE) is limited to oblique lateral interbody fusion (OLIF) 
and anterior lumbar interbody fusion (ALIF) upon nonavailability of autograft. 
Also, BMP-7 or human osteogenic peptide-1 (OP-1) was given an FDA Humanitarian 
Device Exemption in 2004 [44, 45], but later studies [46] ultimately led to the FDA 
rejection of Pre-Market Approval of OP-1 in April 2009.
5.1.1.2 Platelet-derived growth factor (PDGF)
Platelets, monocytes, and endothelial cells are responsible for production of 
PDGF. They recruit various inflammatory cells at the fracture site resulting in 
increased cellular proliferation and collagen deposition. The potential use of PDGF 
has been suggested in the treatment of osteoporosis and bone healing. It is thought 
that recombinant PDGF-BB form assists to release the pericytes from the abluminal 
side to release free and activated MSCs [47, 48].
5.1.1.3 Parathyroid hormone
It is produced by parathyroid glands and is involved in calcium and bone 
metabolism. It is suspected that it might accelerate fracture healing and might 
reduce overall fracture risk [49, 50]. According to reports, PTH can exert anabolic 
as well as catabolic effect on bone metabolism. This feature depends extensively 
on the duration of administration wherein continuous administration results in 
bone resorption, while intermittent administration leads to increased bone deposi-
tion and induction of IGF-1 [51, 52]. Thus, it is speculated as a potential agent for 
osteoporosis treatments.
5.1.1.4 Insulin-like growth factor (iLGF)
The recombinant human insulin-like growth factor-1 (rhIGF-1) is also called 
mecasermin (International Nonproprietary Name (INN)). Children who are very 
short of their age are the target group of the product [53] and are FDA approved 
for the mentioned condition called severe primary Insulin IGF-1 deficiency under 
the trade name of INCRELEX. The FDA approval (in Aug, 2005) was based on five 
clinical trials of the drug (subcutaneously injected), of which four were open-label 
studies and one was double-blinded and placebo-controlled. The integrated results, 
followed up each year for 8 years, showed a considerable increase in height velocity 
(HV) with reference to pre-treatment [54]. HV is calculated between consecutive 
annual study visits as the difference in height, divided by the difference in age [55].
5.2 Synthetic grafts
Synthetic materials that are used for grafting should also possess the properties 
of biocompatibility, bioresorbability, osteoconductivity, osteoinductivity, cost-
effectiveness, and the ease of use to make an ideal grafting material. It should also 
possess the similar features of cortical or cancellous bone which include toughness, 
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modulus of elasticity, and compressive strength. With all these specificities and 
different mechanism of actions, a large number of synthetic bone alternatives have 
emerged which can be used for orthopedic applications.
5.2.1 Ceramic-based bone grafts
Ceramic-based grafts are ionically bonded inorganic preparations, which can 
be described as a family of materials with a wide variety of composition, porosity, 
manufacturing, and structure. Calcium sulfate, hydroxyapatite, tricalcium phos-
phate, bioactive glasses (silicon dioxide, calcium oxide, phosphorous pentoxide, 
and sodium oxide), and synthetic hydroxyapatite come under this category. Not 
only this group of materials varies in terms of material properties, but also differs in 
biodegradability, mechanistic strength, and binding. Glass ionomers have been used 
to seal defects in the skull, sinus augmentations, and otorhinolaryngologic surgeons 
for auditory ossicular reconstructions [56]. They are also used for the application of 
orbital implants, ossicular replacements, and prosthetic joint linings [57]. Calcium 
phosphate does not show any osteogenic properties; however, this material is used 
with the combination of hydroxyapatite and tricalcium phosphate and calcium 
carbonate and monocalcium phosphate monohydrate. This mixture is used as an 
injectable into the bone defect site, to harden. This product undergoes long-term 
remodeling, and the graft is eventually replaced with the in-growth of new bone 
[58, 59]. Hydroxyapatite-based materials are used for coat implants because of their 
great osteo-integrative capabilities [60, 61].
Over all, ceramic-based bone grafts are specifically found useful in iliac crest 
bone grafting and as a bone graft extender in lumbar spine fusion procedures 
[62]. The special feature of ceramic-based graft is their porosity, which is helpful 
in adhesion of mesenchymal cells, and later gets differentiated into osteoblasts. 
Further, this group of grafts is superior as the benefits of its different constituents 
can be availed simultaneously leading to better bone regeneration [63]. Some of the 
commercially available synthetic bone graft substitutes are mentioned in Table 3.
5.3 Polymer-based bone grafts
Polymer-based grafts can be broadly grouped as synthetic or natural polymer-
based grafts and can further be classified as biodegradable and nonbiodegradable 
substitutes. This category of grafting materials is specifically utilized for dental 
implants, as they are found helpful in restoring of edentulous site in the lost tooth. 
In the case of long bone-related congenital defects, or cases requiring bone segment 
replacements after invasion of malignant tissues, polymer-based grafts (vascular fib-
ulas) are found helpful in restoring skeletal integrity. Other polymers like chitosan, 
collagen, gelatin, and poly lactic acid (PLA) are reported to exhibit improved bone 
regeneration capabilities both in vitro and in vivo when combined with hyaluronic 
acid [64]. Another advantage shown by these materials is that of better bone-matrix 
interference since they also act as bio-mimetic, thus helping in deposition, precipita-
tion, and enhancing formation of calcium phosphate [65]. The type of commercially 
available polymer-based bone graft substitute is mentioned in Table 4.
5.4 Tissue engineering and cell-based bone graft
The interdisciplinary field of tissue engineering seeks to combine the bone graft 
substitutes to stimulatory effects of growth factors, (bone morphogenetic proteins 
and osteogenic proteins) to provide structural support and promote more rapid bone 
growth and healing. The prime aim of the bone tissue engineering approach is to 
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guide and enhance osteogenic differentiation of stem cells into 3D constructs, so that 
later it can be engineered successfully into applicable bone constructs. The limitation 
in availability of both allografts and autografts can be addressed to a great extent by 
tissue engineered bones or healing of fracture critical defects. The tissue engineering 
approach for bone grafts differ from other approaches, in the fact that in earlier case, 
Commercial 
product 
(name)
Substitute materials Properties Applications
Osteograf Ceramic Osteoconductive, limited 
osteoinductive when 
mixed with bone marrow
Bone void filler
NovaBone Bioactive glass Osteoconductive, limited 
osteoinductive when 
mixed with bone marrow
Filling surgical or traumatic 
bone gaps
Osteosat Surgical grade 
calcium phosphate
Osteoconductive and 
bioresorbable
Hip and knee joint repair
Calceon 6 Calcium sulfate Osteoconductive and 
bioresorbable
Bone void filler; provides 
strength
Norian Monocalcium 
phosphate, tricalcium 
phosphate, and 
calcium carbonate
Good compressive 
strength
Skull bone defect; injectable 
paste, craniofacial 
reconstructions
Hard tissue-
replacement 
(HTR)
Poly methyl 
methacrylate 
(PMMA)
Good strength, 
durable, and surface 
osteoconductive
Craniofacial reconstruction
Alpha BSM Calcium phosphate 
cement
Good compressive 
strength
Dental application for bone 
and cartilage defects
Mimix Synthetic 
hydroxyapatite tetra-
tricalcium phosphate
Good compressive 
strength
Cranial defects
ELIZ (Kyeron) Composed of 
(40%) β-tricalcium 
phosphate and of 
(60%) hydroxyapatite
Ultrahigh porosity, 
biocompatible, and 
osteoconductive
It has been successfully 
implanted in more than 
1200 patients without any 
side-effects.
OSIQ (Kyeron) Fully synthetic 
ultrapure 
nano-hydroxyapatite
Ready to use, injectable, 
and biodegradable
Filling or reconstruction 
of small and medium bone 
defects
AXOZ QS 
(Kyeron)
Resorbable 
phosphocalcic 
compounds and a 
polymer
Injectable and fully 
resorbs
Supports bone growth
COLLAPAT II 
(Symatese)
Composed of a 
collagen structure 
in which ceramised 
hydroxyapatite 
granules are dispersed
Strong hemostatic power, 
completely resorbable 
in a few weeks, and 
osteoconductive
Induces bone substance 
replacement in 
maxillofacial surgery and 
odontostomatology
CopiOs 
(Zimmer 
Biomet) Bone 
Void Filler
Calcium phosphate, 
dibasic (DICAL), and 
highly purified Type I 
bovine collagen
DICAL provides 
significantly more 
calcium and phosphate 
ions at equilibrium than 
either β-TCP or HA
CopiOs paste acts as an 
osteoconductive scaffold for 
the growth of new bone
Table 3. 
List of some commercially available synthetic materials and their applications.
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integration of engineered bone with patients takes place, thus providing specific 
and more resilient treatment for condition [66]. Further tissue engineering is more 
convenient in the case of bone regeneration therapies, as osteogenic differentiation 
can be achieved through multiple stem cell types [67]. The type of scaffolds and cells 
used for tissue engineering graft is discussed in more detail.
5.4.1 Scaffolds
One important requirement for bone tissue engineering is the scaffold, which 
helps in the migration, proliferation, and differentiation of osteogenic cells promot-
ing new bone formation and regeneration [68]. In this regard, it is required that the 
scaffold must be stable, biocompatible, and biodegradable and should be porous 
and permeable for cell seeding, nutrient transport, tissue ingrowth, and vascular-
ization. It should also be osteoconductive, osteoinductive, and osseo-integrative 
in nature. In clinical settings, a wide range of synthetic and natural scaffolds have 
been explored for bone repair and bone tissue engineering. Broadly, these materi-
als can be categorized as composites, ceramics, and polymers, with each having 
specific properties and limitations. Type I collagen polymer matrix serves as a good 
natural material but suffers from low mechanical modulus.
Commercial 
product (name)
Substitute material Properties Applications
Cortoss Polymer system with 
reinforcing particle 
bioactive glass
Forms biological 
interface
Augmentation of screws 
in osteoporotic bone (hip, 
spine, etc.)
Open porosity 
polylactic acid 
polymer (OPLA)
Polylactic acid Osteoconductive and 
bioresorbable
Articular cartilage 
regeneration
Collagraft Mixture of tricalcium 
phosphate, bovine 
collagen, and 
hydroxyapatite
Bioresorbable and 
osteoconductive
Use for the treatment of 
long bone fracture and 
void filling
DynaGraft Demineralized bone 
matrix
Heat sensitive 
copolymer, injectable 
gel, limited 
osteo-induction
Dental bone graft 
substitute
MedPor Porous polyethylene Higher porosity Orbital reconstruction 
and facial contouring
Collapro/matrix Human collagen in 
lyophilized strip
Lack of immunogenic 
property
Use in development
Healos Hyaluronic acid-coated 
collagen sponge
Osseo-inductive 
property
Replacement of 
autograft/autograft 
extender for spinal fusion
Immix PGA/PLA polymer to be 
produced in chip, flex 
forms
Provides structural 
support
Bone graft extender
OsteoScaf 
(Bonetec)
Macroporous 
poly(lactide-co-
glycolide)/calcium 
phosphate (PLGA/ CaP) 
foam matrices
Fully resorbable, 
osteoconductive, and 
mechanically robust
Heal tissue defects
Table 4. 
List of some commercially available polymer-based graft materials and their applications.
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One important group of scaffold, which has been extensively used for tissue 
engineering, is demineralized bone matrix (DBM). DBM is typically produced 
from allograft bone by the acid extraction method (known as decalcification). 
Based on manufacturing techniques, DBM may be presented in different forms like 
sponges, freeze-dried powder, gel, paste, injectable putty, or strips. It is basically 
a decalcified allograft retaining collagen and noncollagenous proteins [69]. It is 
osteoconductive as well as osteoinductive but has no osteogenic property due to its 
processing. Recently, it is being used in conjunction with cancellous/cortical bone 
chips. The unlimited availability and reduced immune response owing to acidic 
demineralization give it superiority while it is generally used as a bone graft additive 
in spine fusions [70]. The types of DBM bone graft substitute which is commer-
cially available are mentioned in Table 5.
5.4.2 Cell type involved in bone tissue engineering
A variety of in vitro culture protocols are used in bone tissue engineering, which 
requires use of growth factors and cytokines along with specialized dynamic bio-
reactors. It also requires a large scale of bone extracellular matrix-producing cells, 
primarily the MSCs. In this regard, the adult bone marrow stem cells (BMSCs) are 
the cells of choice for tissue engineering. The quantity of the isolated stem cells var-
ies between patients and is indirectly proportional to patient’s age [71, 72]. Also, the 
isolated cells should have high biosynthetic activity, expression of osteogenic mark-
ers, and right cell phenotype. Another source for cell-based bone tissue engineering 
is the adipose tissue which consists of adipose stem cells (ASCs). They undergo 
differentiation into several cell lineages such as osteogenic, chondrogenic, and 
endothelial. Comparative studies of ASCs and BMSCs have shown that they share 
their surface antigen expression pattern involving CD44, CD71, CD90, and CD105 
[73]. However, there are differences too, such as the BMSCs mark the absence of 
hematopoietic and endothelial lineage markers [74–76]. Researchers are currently 
investigating the ability of other multipotent cells such as periosteum, umbilical 
cord, cord blood, and fetal tissues to be used for bone tissue engineering [77].
5.4.3 In-vitro culturing
In this approach, bone marrow is harvested from the patient, followed by in vitro 
culturing and seeding them on scaffolds prior to implantation into the same patient 
for tissue regeneration. The bone repair process required many cell types. These 
cell types are involved in many inflammatory and angiogenic responses and play 
an important role in development of the bone formation mechanisms. They release 
cytokines and various growth factors like PDGF, BMPs, VEGF, and interleukins 
Market 
name
Allograft 
type
Form of/additive with Carrier used
Grafton DBM Gel, putty, and flexible 
sheets
Glycerol carrier
Opteform DBM Cortical bone chips Gelatin carrier
Osteofil DBM Injectable bone paste Collagen-based hydrogel matrix
Dynagraft DBM Syringe Pleuronic reverse phase copolymer
Orthoblast DBM Cancellous bone Bioresorbable reverse phase copolymer
Table 5. 
Marketed DBM-based bone graft substitutes.
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that attract and simulate the mesenchymal stem cells (MSCs), which are directly 
involved in bone repair. However, cell sourcing for bone regeneration is still a 
critical issue for cell-based therapies that need to be addressed. Also, for the sake 
of achieving homogenous growth in 3D environment, a new bioreactor cultivation 
system with mass transport capabilities has been explored [78].
5.4.4 In-vivo studies on bone graft applications
Multiple reports have been published showing not only the application of bone 
tissue engineering in the case of ectopic bone formation (nonbone environment) 
[79] but also in orthotropic bone formation (bone environment) [80]. In 1991, 
Caplan first reported the usage of autologous stem cells for fast and specific skeletal 
tissue repair. Mesenchymal stem cells (MSCs) or mesenchymal colony-forming 
cells (CFU-F) were identified as cell type present in the bone marrow, which have 
the capability to differentiate into different cell types of bone [81]. In 2004, first 
time successful transplantation in humans was reported, where lamellar bone was 
regenerated and repaired by infusing periosteum-derived osteoblasts for 90 days 
[82]. Thus, bone marrow has been recognized as a source of MSCs and other 
osteogenic cells, with relative ease of cell collection using the aspiration method 
[83]. Ever since the identification and recognition of MSCs for repair and engineer-
ing of mesenchymal tissues like cartilage and bone, new cell types and putative 
strategies have been explored vastly. Among newly developed cell types for bone 
tissue engineering, deciduous dental pulp-derived stem cells and adipose derived 
cells were the prominent one showing osteogenic potential [84]. Successful tissue 
engineering-based bone regeneration depends on multiple factors like the number 
of healthy osteogenic cells transplanted, the use of proper scaffold for seeding the 
cells at the site of regeneration, enough vascularization of repair site, and osteo-
genic differentiation factors. The report provided by Coventry and Tapper [62] 
has proved successful regeneration of ectopic bones in rodent models, fulfilling 
all the above-mentioned requirements using ceramic based scaffolds [85]. Further 
bone marrow aspirate and plasmid-rich plasma approaches have been explored for 
facilitating effective tissue engineering-based grafts.
In addition to these materials, research is still continuing to modify the products 
for the production of graft materials, which possess all the properties of ideal 
bone graft. A multidisciplinary approach will be required to improve implanted 
cell survival on biomaterial substrate with addition of cytokines and other growth 
factors for prompt new bone ingrowths. This will yield a bony union that resembles 
natural form and structure. However, the unavailability of widely accepted specific 
guidelines, standardizing minimum standard for bone grafts, is one of the limiting 
factors. Also, the size of in vitro grown tissue grafts is often found to be small, in the 
case of critical size defects.
6. Conclusion and future perspective
The challenge of bone loss and other musculoskeletal complications during 
surgeries is well recognized, and to address the same issue, different grafting 
substitutes have emerged. These bone regeneration grafts can be broadly catego-
rized as natural and synthetic grafting materials. Autograft and allograft comprise 
natural grafting substitutes and between these, allografts are gaining ground 
and more acceptability with time. There have been revolutionary changes during 
the past decade, which bring allograft as a first alternative after autograft, which 
were subsequently interchanged and/or replaced by demineralized bone matrix in 
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certain circumstances [83]. The selection of ideal bone graft substitute materials is 
a difficult task and often lacks substantial scientific backing. However, it is a very 
fast and broad field of investigation. Current trends remarkably increase the use of 
synthetic bone graft as alternatives. The introduction of cost-effective, biologically 
improved synthetic materials that owe the property of ideal bone graft addresses 
the present clinical needs for the optimal treatment. It is not mandatory to use these 
synthetic materials alone for reconstructive procedures. However, when it used in 
the right situations and in combination with autologous, allograft, or other synthet-
ics, in combination with growth factors, they give potentially more desirable results.
With the advancement of biomechanical research, an interdisciplinary field of 
tissue engineering has emerged. Limitations associated with the autologous bone 
grafting method can be addressed to a great extent with the help of bone tissue 
engineering. However, selection of optimized combinations of cells, synthetic 
materials (scaffolds) and factors will remain a challenging and complex process. 
One of them is the selection of materials and cells. This may include the materials, 
which possess appropriate mechanical properties, degradation rates, and chemical 
functionality; likewise, for stem cells, it should be isolated from patient-specific 
cells from the appropriate lineage and directed down on a scaffold construct to heal 
the proper bone tissues. Cheaper and safer alternatives will probably emerge with 
a better understanding of the inherent ability of material to induce bone formation 
after bone graft implantation.
Thus, these developments must also be nurtured and monitored by the group of 
clinicians and researchers with the knowledge of medical necessity, basic biological 
principles, and commercial practicality. This may be used for the production of 
versatile, and easy to implement, allowing for bioengineered bone grafts to more 
quickly make the leap from bench to bedside. This will help to improve the quality 
of life of pediatric and adult patients suffering from bone disease and/or disorder. 
This may be helpful for bridging the gap between bone tissue engineering research 
and its clinical implications.
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